Salla disease carrier status, and what one detected variant does not settle
Of the Finnish founder conditions on our carrier panel, this is one of the few a consumer DNA test actually reports. That makes it the right page on which to be precise about what a detected variant does and does not settle.
Also known as: SLC17A5 carrier, free sialic acid storage disorder, FSASD, sialic acid storage disease.
- Gene
- SLC17A5
- Inheritance
- Autosomal recessive
- Carrier frequency
- roughly 1 in 100 in northeastern Finland and among families from the Salla region, where the founder change is concentrated; rare elsewhere
What it is
Salla disease is a recessive storage condition caused by changes in SLC17A5, the gene for a transport protein that moves free sialic acid out of the lysosome. When the transporter does not work, sialic acid accumulates inside lysosomes throughout the body, and the tissue that suffers most for it is the nervous system. The condition is named after the municipality of Salla, in northeastern Finnish Lapland, where the founder change behind it is concentrated.
GeneReviews treats Salla disease as the milder end of a spectrum it calls free sialic acid storage disorder, or FSASD, with a more severe infantile form at the other end. The two are the same biochemical problem at different intensities, and where an individual falls on that spectrum turns out to depend on which combination of changes they carry. In the milder form, GeneReviews notes that low muscle tone is often the first thing recognised, at around six months of age, with progressive difficulties following.
There is no curative therapy for any point on the spectrum. GeneReviews describes management as symptomatic and supportive. That is a straightforward statement of where the field is, and it is the context in which a carrier result should be read: the value of knowing is in reproductive planning and in shortening somebody else's diagnostic search, not in starting a treatment.
How it is inherited
Salla disease is autosomal recessive. A carrier has one changed copy of SLC17A5 and one working copy, which transports enough sialic acid, and the carrier is healthy. If a reproductive partner also carries an SLC17A5 change, each pregnancy has a one in four chance of an affected child.
The Finnish founder change is p.Arg39Cys, and it is common enough within this condition to dominate it worldwide: GeneReviews reports that roughly 80% of reported individuals with FSASD carry it, in one copy or in two. That is an unusually concentrated picture for a rare disease, and it is what makes the next fact matter rather than being a footnote.
GeneReviews sets out a genotype and phenotype relationship here that runs against the intuition most people bring to recessive genetics. Two copies of the Finnish founder change gives Salla disease with its slow clinical course. One copy of the founder change together with a different disease-causing SLC17A5 change gives what GeneReviews calls intermediate severe FSASD. In other words the combination involving a second, rarer variant is the more severe one, not the milder one. Carrying the well-known change twice is, in this particular gene, the gentler outcome.
What your raw DNA file can and cannot tell you
Unusually for this family of pages, the answer about consumer chip products is not simply no. 23andMe's published carrier status list, re-checked in August 2026, does include Salla disease. A customer of theirs may already hold a result about this gene, which is worth acknowledging plainly rather than talking around.
What such a result establishes, and what it does not, is where the previous section earns its place. Consumer carrier reports are variant-specific by design: they test a defined set of positions and report on those, which is a different exercise from reading a gene. For most conditions that limitation degrades gracefully, giving a strong positive and a weak negative. For this one there is a sharper edge. A test built around the founder variant can tell you whether that variant is present in one copy or two. It cannot distinguish someone who carries the founder change and nothing else, who is a healthy carrier, from someone who carries the founder change alongside a second SLC17A5 variant that was never typed, which is the combination GeneReviews associates with more severe disease. Both return the same result: one copy found. Aimosti does not issue carrier status from a chip file at all, for this gene or any other, so this is not us claiming a better chip. It is the reason we read files that cover the whole gene.
A whole-genome VCF or gVCF is what our carrier module reads, and it looks across SLC17A5 rather than at chosen positions, so a second rarer change is within reach of the method rather than outside it by construction. Two honest limits go with that. This is not clinical carrier screening and it is not a substitute for a validated, gene-targeted carrier test arranged through a clinic. And the reassuring context belongs here too: FSASD in all its forms declares itself in infancy or early childhood, so an adult reading a carrier result is a carrier. The distinction drawn on this page matters for interpreting a result and for a family with an undiagnosed child, not because a healthy adult should be re-reading their own report with alarm.
A genotyping chip reads only a few hundred thousand pre-selected positions, about 0.02% of your genome, chosen for common variation. It does not sequence the rest, so it cannot find the rare or novel pathogenic variants the clinical and carrier modules look for: a “no finding” from chip data means “this chip never looked”, far more so than with whole-genome sequencing. Chip data suits common-variant traits, pharmacogenomic tag SNPs, and haplogroup ancestry, not clinical or carrier screening.
Common questions
23andMe told me I am a Salla disease carrier. Is that the same as what you would tell me?
It is the same finding, reached by a narrower method. Consumer carrier reports type a defined set of variants and report on those, which for a founder condition would normally centre on the common Finnish change. Our carrier module reads a sequencing file across the whole gene, so it can also see rarer changes that a fixed set of positions was never designed to catch. For a healthy adult the practical answer is usually identical. The difference shows up when a second, rarer variant is present, because a variant-specific test reports that person exactly as it reports a carrier.
Why would carrying two different variants be worse than carrying the same one twice?
It is counter-intuitive but it is what the literature records. GeneReviews states that homozygosity for the Finnish founder variant p.Arg39Cys produces Salla disease with its slow course, while compound heterozygosity for that variant together with a different SLC17A5 change produces intermediate severe FSASD. The founder variant appears to leave more residual function than many of the alternatives, so two copies of it is a milder combination than one of it plus something more damaging. This page reports the association; the mechanism is a question for the primary literature.
Could I have Salla disease and not know?
Realistically, no. Across the whole free sialic acid storage spectrum the condition becomes apparent in infancy or early childhood, and GeneReviews notes that in the milder form low muscle tone is often recognised at around six months. There is no adult-onset version that has been hiding. An adult with a carrier result is a carrier, and the result is information about what could be passed on rather than about their own health.
Why is it called Salla disease?
After the municipality of Salla in northeastern Finnish Lapland, where the founder change is concentrated and where the condition was first characterised. Naming a disease after the place its founder variant clustered was common practice in twentieth century genetics and it produced several of the Finnish Disease Heritage names. It describes population history, not a claim that the condition is confined to that municipality today.
Is there any treatment?
No curative therapy exists. GeneReviews describes management as symptomatic and supportive, directed at the specific difficulties as they arise. Anyone dealing with this in a family should be under the care of a metabolic specialist, and a carrier result on its own is not a reason to seek treatment, because carriers do not have the condition.